Pitt Shield

Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors: Xhima K, Nabbouh F, Hynynen K, Aubert I, Tandon A

The characteristic progression of Lewy pathology in Parkinson's disease likely involves intercellular exchange and the accumulation of misfolded α-synuclein amplified by a prion-like self-templating mechanism. Silencing of the α-synuclein gene could provide long-lasting disease-modifying benefits by reducing the requisite substrate for the spreading aggregation. As a result of the poor penetration of viral vectors across the blood-brain barrier, gene therapy for central nervous system disorders requires direct injections into the affected brain regions, and invasiveness is further increased by the need for bilateral delivery to multiple brain regions. Here we test a noninvasive approach by combining low-intensity magnetic resonance-guided focused ultrasound and intravenous microbubbles that can transiently increase the access of brain impermeant therapeutic macromolecules to targeted brain regions. Transgenic mice expressing human α-synuclein were subjected to magnetic resonance-guided focused ultrasound targeted to 4 brain regions (hippocampus, substantia nigra, olfactory bulb, and dorsal motor nucleus) in tandem with intravenous microbubbles and an adeno-associated virus serotype 9 vector bearing a short hairpin RNA sequence targeting the α-synuclein gene. One month following treatment, α-synuclein immunoreactivity was decreased in targeted brain regions, whereas other neuronal markers such as synaptophysin or tyrosine hydroxylase were unchanged, and cell death and glial activation remained at basal levels. These results demonstrate that magnetic resonance-guided focused ultrasound can effectively, noninvasively, and simultaneously deliver viral vectors targeting α-synuclein to multiple brain areas. Importantly, this approach may be useful to alter the progression of Lewy pathology along selected neuronal pathways, particularly as prodromal PD markers improve early diagnoses. © 2018 International Parkinson and Movement Disorder Society.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To test whether MR-guided focused ultrasound combined with intravenous microbubbles can noninvasively deliver AAV9-shRNA targeting α-synuclein to multiple brain regions and reduce α-synuclein expression in transgenic mice.
Animal model / Human subject Mus musculus (transgenic mice expressing human α-synuclein); strain: None; age: None; sex: None
Disease model Parkinson's disease
MRI or image guidance method MR-guided focused ultrasound (MRI guidance)
Targeted brain region(s) Hippocampus, Substantia Nigra, Olfactory Bulb, Dorsal Motor Nucleus
Cargo name and characteristics Adeno-associated virus serotype 9 (AAV9) vector encoding a short hairpin RNA (shRNA) targeting human α-synuclein (gene-silencing RNA)
Route of administration intravenous (AAV9 vector administered intravenously in combination with MR-guided focused ultrasound to target brain regions)

Outcomes and Safety

Summary of Outcomes Low-intensity MR-guided focused ultrasound (MRgFUS) with intravenous microbubbles enabled noninvasive, simultaneous delivery of AAV9-shRNA to four brain regions and produced reduced α-synuclein immunoreactivity one month after treatment while synaptophysin, tyrosine hydroxylase, cell death, and glial activation remained unchanged. The successful approach was low-intensity MRgFUS combined with IV microbubbles to deliver AAV9-shRNA to targeted regions.
Duration of biological effect 1 month
Safety-related matter No adverse effects were reported: one month after treatment synaptophysin and tyrosine hydroxylase were unchanged, and cell death and glial activation remained at basal levels.

Brain Region

Ultrasound Parameters

Focal Characteristics Focal depth: None; Focal length: None; Aperture size: None
Treatment frequency single

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search